Transitional Cell Carcinoma

Study title

Rapid release paclitaxel particles for intravesical treatment of transitional cell carcinoma of the bladder.

Purpose of study

The goal of this study is to evaluate the targeting advantage of paclitaxel-loaded particles in treatment of transitional cell carcinomas (TCC) of the bladder in dogs.

Inclusion criteria

Diagnosis of TCC of the bladder must be made via histopathology; biopsies can be taken during the first cystoscopy in the study. Dogs with evidence of distant metastases on abdominal ultrasound or thoracic radiographs are not eligible.

Diagnostics, treatment and compensation

Patients will be under general anesthesia for each intravesical treatment via cystoscopy. Paclitaxel will be instilled into the urinary bladder and drained prior to recovery from anesthesia. Blood, urine and tumor specimens will be collected to allow determination of drug concentrations in these samples.

The study will pay for approximately $1,500 of the costs for treating each dog. The client will be responsible for the remainder, which we estimate will be approximately $500 to $600.

For more information on this study, please contact Dr. Francisco Alvarez at clinicaltrials [at] cvm [dot] osu [dot] edu.